REGENXBIO Inc. reported $174M of revenue over the trailing twelve months, +12% on the year before. 10 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $174M (to Q2 2026). Net income: −$196M, trailing twelve months to Q2 2026. Free cash flow: −$250M, trailing twelve months to Q2 2026. Operating margin: −411%, trailing twelve months to Q2 2026.

RGNXREGENXBIO Inc.

Healthcare

$8.08-23% 1Y

$8.08

$5.6552 weeks$15.98

RGNX as reported

REGENXBIO Inc. reported $174M of revenue over the trailing twelve months, +12% on the year before. 10 reported series are charted on this page, each one as filed.

$174M

Revenue, trailing twelve months · to Q2 2026 · +12% against the twelve months before

Net income: −$196M
Net income · +12% year on year · trailing twelve months to Q2 2026
Free cash flow: −$250M
Free cash flow · +175% year on year · trailing twelve months to Q2 2026
Operating margin: −411%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for RGNX, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$174M	+12%	Q2 2026
Net income	−$196M	+12%	Q2 2026
EPS	−$3.79	+10%	Q2 2026
Gross margin	61%	n/a	Q4 2024 · 6 quarters behind
Operating margin	−411%	n/a	Q2 2026
Net margin	−454%	n/a	Q2 2026
ROE	−487%	n/a	Q2 2026
ROA	−53%	n/a	Q2 2026
Free cash flow	−$250M	+175%	Q2 2026
P/E	13.2	n/a	Q3 2022 · 15 quarters behind

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.